Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01620060 · ClinicalTrials.gov registry record · Phase 1
Lurasidone Pediatric Pharmacokinetics Study
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
NCT01620060 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 105 participants.
The verdict
NCT01620060, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, multicenter, single and multiple ascending lurasidone dose study in subjects from 6 to 17 years old with schizophrenia spectrum, bipolar spectrum, autistic spectrum disorder, or other psychiatric disorders.
Interventions
- DRUG Lurasidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2012-06 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01620060
The ClinicalTrials.gov registry entry for NCT01620060 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lurasidone is the first listed.
NCT01620060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01620060 about?
NCT01620060 is a clinical study titled "Lurasidone Pediatric Pharmacokinetics Study". This is a Phase 1, open-label, multicenter, single and multiple ascending lurasidone dose study in subjects from 6 to 17 years old with schizophrenia spectrum, bipolar spectrum, autistic spectrum disorder, or other psychiatric disorders.
What is the current status of trial NCT01620060?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2012-06. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01620060?
The interventions under investigation include: Lurasidone (DRUG).
Who is sponsoring clinical trial NCT01620060?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.